{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:56:28Z","timestamp":1792601788034,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009268","name":"Alport Syndrome Foundation","doi-asserted-by":"publisher","award":["2020-2022"],"award-info":[{"award-number":["2020-2022"]}],"id":[{"id":"10.13039\/100009268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.xkme.2023.100631","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T15:34:59Z","timestamp":1679412899000},"page":"100631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Alport Syndrome: Clinical Spectrum and Therapeutic Advances"],"prefix":"10.1016","volume":"5","author":[{"given":"Vanessa De","family":"Gregorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Bilge","family":"Caparali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Shojaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Ricardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumita","family":"Barua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3454","key":"10.1016\/j.xkme.2023.100631_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","article-title":"Hereditary familial congenital haemorrhagic nephritis","volume":"1","author":"Alport","year":"1927","journal-title":"Br Med J"},{"issue":"10","key":"10.1016\/j.xkme.2023.100631_bib2","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1097\/01.ASN.0000141462.00630.76","article-title":"The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family","volume":"15","author":"Hudson","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2023.100631_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-12-363706-2.50008-8","article-title":"Structure and biosynthesis of basement membranes","volume":"6","author":"Kefalides","year":"1973","journal-title":"Int Rev Connect Tissue Res"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: achieving early diagnosis and treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1432-1033.1981.tb05690.x","article-title":"A\u00a0network model for the organization of type IV collagen molecules in basement membranes","volume":"120","author":"Timpl","year":"1981","journal-title":"Eur J Biochem"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF00283147","article-title":"Alteration in the distribution of type IV collagen in glomerular basal laminae in diabetic rats as revealed by immunocytochemistry and morphometrical approach","volume":"28","author":"Bendayan","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.xkme.2023.100631_bib7","first-page":"1","article-title":"Structure, development, and molecular pathology of basement membranes","volume":"29","author":"Timpl","year":"1986","journal-title":"Int Rev Exp Pathol"},{"issue":"1-2","key":"10.1016\/j.xkme.2023.100631_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0014-5793(87)81155-9","article-title":"Complete primary structure of the \u03b11-chain of human basement membrane (type IV) collagen","volume":"225","author":"Soininen","year":"1987","journal-title":"FEBS Lett"},{"issue":"18","key":"10.1016\/j.xkme.2023.100631_bib9","doi-asserted-by":"crossref","first-page":"8496","DOI":"10.1016\/S0021-9258(18)47441-8","article-title":"Extensive homology between the carboxyl-terminal peptides of mouse alpha 1(IV) and alpha 2(IV) collagen","volume":"262","author":"Kurkinen","year":"1987","journal-title":"J\u00a0Biol Chem"},{"issue":"36","key":"10.1016\/j.xkme.2023.100631_bib10","doi-asserted-by":"crossref","first-page":"19488","DOI":"10.1016\/S0021-9258(19)77660-1","article-title":"The complete primary structure of the alpha 2 chain of human type IV collagen and comparison with the alpha 1(IV) chain","volume":"263","author":"Hostikka","year":"1988","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1432-1033.1984.tb08404.x","article-title":"Structure of human-basement-membrane (type IV) collagen. Complete amino-acid sequence of a 914-residue-long pepsin fragment from the alpha 1(IV) chain","volume":"143","author":"Babel","year":"1984","journal-title":"Eur J Biochem"},{"issue":"12","key":"10.1016\/j.xkme.2023.100631_bib12","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xkme.2023.100631_bib13","first-page":"117","article-title":"Studies on the molecular composition and degradation of type IV procollagen","volume":"108","author":"Tryggvason","year":"1984","journal-title":"Ciba Found Symp"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(86)90259-X","article-title":"Arg-Gly-Asp: a versatile cell recognition signal","volume":"44","author":"Ruoslahti","year":"1986","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.xkme.2023.100631_bib15","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1073\/pnas.81.19.5985","article-title":"Variants of the cell recognition site of fibronectin that retain attachment-promoting activity","volume":"81","author":"Pierschbacher","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.xkme.2023.100631_bib16","doi-asserted-by":"crossref","first-page":"9783","DOI":"10.1016\/S0021-9258(17)42768-2","article-title":"Characterization of the procollagen IV cleavage products produced by a specific tumor collagenase","volume":"259","author":"Fessler","year":"1984","journal-title":"J\u00a0Biol Chem"},{"issue":"14","key":"10.1016\/j.xkme.2023.100631_bib17","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1016\/S0021-9258(18)68680-6","article-title":"H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen","volume":"263","author":"Collier","year":"1988","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-5793(88)81365-6","article-title":"Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin","volume":"233","author":"H\u00f6yhty\u00e4","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1016\/j.xkme.2023.100631_bib19","series-title":"Mammalian Collagenases: Aspects of Regulation (Life Chemistry Reports Series)","author":"Woolley","year":"1984"},{"key":"10.1016\/j.xkme.2023.100631_bib20","series-title":"Extracellular Matrix Biochemistry","first-page":"1","article-title":"Molecular and aggregate structure of the collagens","author":"Piez","year":"1984"},{"issue":"16","key":"10.1016\/j.xkme.2023.100631_bib21","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1016\/S0021-9258(18)47648-X","article-title":"Localization of the Goodpasture epitope to a novel chain of basement membrane collagen","volume":"262","author":"Butkowski","year":"1987","journal-title":"J\u00a0Biol Chem"},{"issue":"26","key":"10.1016\/j.xkme.2023.100631_bib22","doi-asserted-by":"crossref","first-page":"13374","DOI":"10.1016\/S0021-9258(18)37714-7","article-title":"Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV","volume":"263","author":"Saus","year":"1988","journal-title":"J\u00a0Biol Chem"},{"issue":"10","key":"10.1016\/j.xkme.2023.100631_bib23","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1016\/S0021-9258(19)39384-6","article-title":"Glomerular basement membrane. Identification of a fourth chain, alpha 4, of type IV collagen","volume":"265","author":"Gunwar","year":"1990","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0021-9258(18)48422-0","article-title":"The alpha 4(IV) chain of basement membrane collagen. Isolation of cDNAs encoding bovine alpha 4(IV) and comparison with other type IV collagens","volume":"267","author":"Mariyama","year":"1992","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib25","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1073\/pnas.87.4.1606","article-title":"Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome","volume":"87","author":"Hostikka","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.xkme.2023.100631_bib26","doi-asserted-by":"crossref","first-page":"13758","DOI":"10.1016\/S0021-9258(18)77414-0","article-title":"Complete primary structure of the triple-helical region and the carboxyl-terminal domain of a new type IV collagen chain, alpha 5(IV)","volume":"265","author":"Pihlajaniemi","year":"1990","journal-title":"J\u00a0Biol Chem"},{"issue":"5125","key":"10.1016\/j.xkme.2023.100631_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1126\/science.8356449","article-title":"Deletion of the paired \u03b15(IV) and \u03b16(IV) collagen genes in inherited smooth muscle tumors","volume":"261","author":"Zhou","year":"1993","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.xkme.2023.100631_bib28","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1681\/ASN.2020071065","article-title":"Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome","volume":"32","author":"Gibson","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1172\/JCI113057","article-title":"Alport familial nephritis. Absence of 28 kilodalton non-collagenous monomers of type IV collagen in glomerular basement membrane","volume":"80","author":"Kleppel","year":"1987","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib30","first-page":"1024","article-title":"Molecular cloning of alpha 5(IV) collagen and assignment of the gene to the region of the X chromosome containing the Alport syndrome locus","volume":"46","author":"Myers","year":"1990","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0888-7543(92)90157-N","article-title":"Colocalization of the genes for the alpha 3(IV) and alpha 4(IV) chains of type IV collagen to chromosome 2 bands q35-q37","volume":"13","author":"Mariyama","year":"1992","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/ng0994-77","article-title":"Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome","volume":"8","author":"Mochizuki","year":"1994","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s10157-018-1629-4","article-title":"A\u00a0review of clinical characteristics and genetic backgrounds in Alport syndrome","volume":"23","author":"Nozu","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"4960","key":"10.1016\/j.xkme.2023.100631_bib34","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.2349482","article-title":"Identification of mutations in the COL4A5 collagen gene in Alport syndrome","volume":"248","author":"Barker","year":"1990","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ki.1993.8","article-title":"Molecular genetics of Alport syndrome","volume":"43","author":"Tryggvason","year":"1993","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jemt.20564","article-title":"Mammalian collagen IV","volume":"71","author":"Khoshnoodi","year":"2008","journal-title":"Microsc Res Tech"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1515\/hsz-2018-0317","article-title":"Complexity of type IV collagens: from network assembly to function","volume":"400","author":"Wu","year":"2019","journal-title":"Biol Chem"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1523-1755.2000.00250.x","article-title":"Estimating prevalence in single-gene kidney diseases progressing to renal failure","volume":"58","author":"Levy","year":"2000","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000182941","article-title":"Renal cysts in pediatric autopsy material","volume":"33","author":"Mir","year":"1983","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/302182","article-title":"Structure of the gene for congenital nephrotic syndrome of the Finnish type (NPHS1) and characterization of mutations","volume":"64","author":"Lenkkeri","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/adc.51.5.344","article-title":"Congenital nephrotic syndrome of Finnish type. Study of 75 patients","volume":"51","author":"Huttunen","year":"1976","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1097-0223(199603)16:3<207::AID-PD834>3.0.CO;2-K","article-title":"Prenatal screening for congenital nephrosis in east Finland: results and impact on the birth prevalence of the disease","volume":"16","author":"Heinonen","year":"1996","journal-title":"Prenat Diagn"},{"issue":"7726","key":"10.1016\/j.xkme.2023.100631_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.xkme.2023.100631_bib44","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/hmg\/ddy409","article-title":"Sequence variants associating with urinary biomarkers","volume":"28","author":"Benonisdottir","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-021-04934-y","article-title":"Population-based studies reveal an additive role of type IV collagen variants in hematuria and albuminuria","volume":"37","author":"Barua","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.xkme.2020.12.007","article-title":"Type IV collagen variants in CKD: performance of computational predictions for identifying pathogenic variants","volume":"3","author":"Shulman","year":"2021","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med. May"},{"issue":"9","key":"10.1016\/j.xkme.2023.100631_bib48","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ekir.2022.06.001","article-title":"Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities","volume":"7","author":"Savige","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.xkme.2023.100631_bib49","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2215\/CJN.03120322","article-title":"Digenic Alport syndrome","volume":"17","author":"Savige","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib50","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1523-1755.2004.00560.x","article-title":"Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene","volume":"65","author":"Pescucci","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/jmedgenet-2014-102822","article-title":"Evidence of digenic inheritance in Alport syndrome","volume":"52","author":"Mencarelli","year":"2015","journal-title":"J\u00a0Med Genet"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1681\/ASN.2005070737","article-title":"Thin basement membrane nephropathy","volume":"17","author":"Tryggvason","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM198901053200103","article-title":"Thin-basement-membrane nephropathy in adults with persistent hematuria","volume":"320","author":"Tiebosch","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"8713","key":"10.1016\/j.xkme.2023.100631_bib54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0140-6736(90)92015-A","article-title":"No author listed. Thin-membrane nephropathy--how thin is thin?","volume":"336","year":"1990","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.xkme.2023.100631_bib55","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1681\/ASN.2007040444","article-title":"COL4A3\/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy","volume":"18","author":"Voskarides","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib56","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib57","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1046\/j.1523-1755.2002.00379.x","article-title":"COL4A3\/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome","volume":"61","author":"Longo","year":"2002","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.xkme.2023.100631_bib58","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/ndt\/4.12.1016","article-title":"Renal prognosis in Alport\u2019s and related syndromes: influence of the mode of inheritance","volume":"4","author":"Pochet","year":"1989","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1076\/1381-6810(200012)2141-HFT217","article-title":"Absence of ocular manifestations in autosomal dominant Alport syndrome associated with haematological abnormalties","volume":"21","author":"Colville","year":"2000","journal-title":"Ophthalmic Genet"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000368519","article-title":"Study of the true clinical progression of autosomal dominant Alport syndrome in a European population","volume":"40","author":"Rosado","year":"2015","journal-title":"Kidney Blood Press Res"},{"issue":"10","key":"10.1016\/j.xkme.2023.100631_bib61","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","article-title":"X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport Syndrome Concerted Action\u201d study","volume":"14","author":"Jais","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.xkme.2023.100631_bib62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ki.2011.452","article-title":"Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations","volume":"81","author":"Temme","year":"2012","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.xkme.2023.100631_bib63","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1681\/ASN.2012100985","article-title":"COL4A3\/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome","volume":"24","author":"Storey","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib64","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/humu.9065","article-title":"Three novel COL4A4 mutations resulting in stop codons and their clinical effects in autosomal recessive Alport syndrome","volume":"20","author":"Dagher","year":"2002","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib65","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/gfv325","article-title":"Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis","volume":"31","author":"Gast","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib66","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ki.2014.305","article-title":"Rare hereditary COL4A3\/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis","volume":"86","author":"Malone","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib67","doi-asserted-by":"crossref","first-page":"672","DOI":"10.2215\/CJN.13711021","article-title":"GWAS of hematuria","volume":"17","author":"Gagliano Taliun","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib69","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2009070784","article-title":"Genotype-phenotype correlation in X-linked Alport syndrome","volume":"21","author":"Bekheirnia","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5414\/CN108561","article-title":"Phenotypic heterogeneity in females with X-linked Alport syndrome","volume":"84","author":"Allred","year":"2015","journal-title":"Clin Nephrol"},{"issue":"9","key":"10.1016\/j.xkme.2023.100631_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161802","article-title":"X- linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype-phenotype correlations","volume":"11","author":"Savige","year":"2016","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib72","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00005792-199909000-00005","article-title":"Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes","volume":"78","author":"Kashtan","year":"1999","journal-title":"Medicine (Baltimore)"},{"issue":"18","key":"10.1016\/j.xkme.2023.100631_bib73","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1113\/jphysiol.2014.274449","article-title":"Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment","volume":"592","author":"Savige","year":"2014","journal-title":"J\u00a0Physiol"},{"issue":"148","key":"10.1016\/j.xkme.2023.100631_bib74","first-page":"563","article-title":"Alport\u2019s syndrome of hereditary nephritis and deafness","volume":"37","author":"Crawfurd","year":"1968","journal-title":"Q\u00a0J Med"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib75","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1053\/j.ajkd.2016.08.002","article-title":"AJKD atlas of renal pathology: Alport syndrome","volume":"68","author":"Fogo","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib76","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00467-011-1868-z","article-title":"Glomerular pathology in Alport syndrome: a molecular perspective","volume":"27","author":"Cosgrove","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib77","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10278-009-9233-5","article-title":"Analysis of the glomerular basement membrane in images of renal biopsies using the split-and-merge method: a pilot study","volume":"23","author":"Kamenetsky","year":"2010","journal-title":"J\u00a0Digit Imaging"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF00858986","article-title":"Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis","volume":"9","author":"Schnaper","year":"1995","journal-title":"Pediatr Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2023.100631_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000481633","article-title":"A\u00a0review of podocyte biology","volume":"47","author":"Garg","year":"2018","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2215\/CJN.08750718","article-title":"Integration of genetic testing and pathology for the diagnosis of adults with FSGS","volume":"14","author":"Yao","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Pt 2","key":"10.1016\/j.xkme.2023.100631_bib81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/eye.1987.34","article-title":"Structure, function and ageing of the collagens of the eye","volume":"1","author":"Bailey","year":"1987","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib82","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.10581014","article-title":"Ocular features in Alport syndrome: pathogenesis and clinical significance","volume":"10","author":"Savige","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib83","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1167\/iovs.08-3323","article-title":"Retinal basement membrane abnormalities and the retinopathy of Alport syndrome","volume":"51","author":"Savige","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.xkme.2023.100631_bib84","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00467-008-0759-4","article-title":"The use of ocular abnormalities to diagnose X-linked Alport syndrome in children","volume":"23","author":"Zhang","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2023.100631_bib85","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/archotol.131.11.1007","article-title":"Distribution of type IV collagen in the cochlea in Alport syndrome","volume":"131","author":"Zehnder","year":"2005","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib86","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0272-6386(96)90540-5","article-title":"In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression","volume":"27","author":"Cohen","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib87","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib88","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib89","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A\u00a0multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.xkme.2023.100631_bib90","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/cells10071815","article-title":"Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, Alport syndrome, and FSGS: a case series to better plan a large-scale study","volume":"10","author":"Boeckhaus","year":"2021","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.xkme.2023.100631_bib91","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.xkme.2023.100631_bib92","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib93","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib94","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib95","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/dom.12403","volume":"17","author":"Kashiwagi","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib97","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib98","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.braindev.2004.09.014","article-title":"A\u00a0novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy","volume":"27","author":"Kimura","year":"2005","journal-title":"Brain Dev"},{"issue":"12","key":"10.1016\/j.xkme.2023.100631_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223954","article-title":"The novel aminoglycoside, ELX-02, permits CTNSW138X translational read-through and restores lysosomal cystine efflux in cystinosis","volume":"14","author":"Brasell","year":"2019","journal-title":"PLOS ONE"},{"issue":"14","key":"10.1016\/j.xkme.2023.100631_bib100","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00018-007-7034-x","article-title":"Aminoglycoside antibiotics: old drugs and new therapeutic approaches","volume":"64","author":"Hermann","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"10.1016\/j.xkme.2023.100631_bib101","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A\u00a0randomized, double-blind, placebo-controlled, multiple dose escalation study to evaluate the safety and pharmacokinetics of ELX-02 in healthy subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib102","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.kint.2016.02.018","article-title":"Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease","volume":"90","author":"Dufek","year":"2016","journal-title":"Kidney Int"},{"issue":"suppl 3","key":"10.1016\/j.xkme.2023.100631_bib103","article-title":"MO033 The dual ETAR\/AT1R blocker sparsentan slows renal disease, improves lifespan, and attenuates hearing loss in Alport mice: comparison with losartan","volume":"35","author":"Cosgrove","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.xkme.2023.100631_bib104","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db15-1413","article-title":"Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy","volume":"65","author":"Boels","year":"2016","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib105","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.cell.2020.06.045","article-title":"Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations","volume":"182","author":"Chen","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.xkme.2023.100631_bib106","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneph.2014.87","article-title":"Lipid biology of the podocyte--new perspectives offer new opportunities","volume":"10","author":"Fornoni","year":"2014","journal-title":"Nat Rev Nephrol. Jul"},{"issue":"5","key":"10.1016\/j.xkme.2023.100631_bib107","first-page":"603","article-title":"Lipotoxicity as a trigger factor of renal disease","volume":"29","author":"Izquierdo-Lahuerta","year":"2016","journal-title":"J\u00a0Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MNH.0b013e32833aa4ac","article-title":"Renal lipid metabolism and lipotoxicity","volume":"19","author":"Bobulescu","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib109","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xkme.2023.100631_bib110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3949\/ccjm.85a.17034","article-title":"Hydroxychloroquine: an old drug with new relevance","volume":"85","author":"Shippey","year":"2018","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2023.100631_bib112","article-title":"Hydroxychloroquine inhibits macrophage activation and attenuates renal fibrosis after ischemia-reperfusion injury","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Immunol"},{"issue":"32","key":"10.1016\/j.xkme.2023.100631_bib113","doi-asserted-by":"crossref","first-page":"14339","DOI":"10.1073\/pnas.0912701107","article-title":"Identification of a microRNA signature of renal ischemia reperfusion injury","volume":"107","author":"Godwin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"121","key":"10.1016\/j.xkme.2023.100631_bib114","doi-asserted-by":"crossref","first-page":"121ra18","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000486398","article-title":"Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study","volume":"47","author":"Chin","year":"2018","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2023.100631_bib116","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000513777","article-title":"Study design and baseline characteristics of the CARDINAL trial: a phase 3 study of bardoxolone methyl in patients with Alport syndrome","volume":"52","author":"Chertow","year":"2021","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib117","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1681\/ASN.2017121317","article-title":"Bardoxolone-the phoenix?","volume":"29","author":"Toto","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2023.100631_bib118","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1681\/ASN.2017101062","article-title":"Should we increase GFR with bardoxolone in Alport syndrome?","volume":"29","author":"Baigent","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.xkme.2023.100631_bib119","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2215\/CJN.02400222","article-title":"Effects of bardoxolone methyl in Alport syndrome","volume":"17","author":"Warady","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.23876\/j.krcp.20.111","article-title":"Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome","volume":"39","author":"Nozu","year":"2020","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.xkme.2023.100631_bib121","first-page":"81","article-title":"Establishment of X-linked Alport syndrome model mice with a Col4a5 R471X mutation","volume":"17","author":"Hashikami","year":"2019","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"10.1016\/j.xkme.2023.100631_bib122","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib123","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1681\/ASN.2013070798","article-title":"Feasibility of repairing glomerular basement membrane defects in Alport syndrome","volume":"25","author":"Lin","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100631_bib124","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41431-019-0537-8","article-title":"New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells","volume":"28","author":"Daga","year":"2020","journal-title":"Eur J Hum Genet"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:25:05Z","timestamp":1762910705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059523000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2590059523000407"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100631","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alport Syndrome: Clinical Spectrum and Therapeutic Advances","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100631"}}